Q-omics provides the consensus-scored C3orf33 profile across patient tissues and cancer cell-line models. C3orf33 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, C3orf33 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, C3orf33 RNA expression shows 19,870 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, KICH, and ACC as cancer lineages where C3orf33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C3orf33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C3orf33 survival associations across molecular data types. C3orf33 RNA expression shows survival associations in the most cancer types (25), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C3orf33 RNA expression–survival associations across cancer types. High C3orf33 expression shows unfavorable associations in LIHC, UCEC, SCLC and DLBC, but favorable associations in KIRC and LUAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for C3orf33 RNA expression.
This table summarizes C3orf33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C3orf33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C3orf33 shows lower tumor expression in KICH, THCA and KIRC and higher tumor expression in LIHC, HNSC and CHOL. The KICH box plot shows higher C3orf33 RNA expression in normal versus tumor tissue (log2 FC = −1.374, t-test p < 0.001).
This table shows molecular features associated with C3orf33 in patient tissues and cancer cell lines. In patient samples, C3orf33 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C3orf33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
